Literature DB >> 11461188

Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease).

P Luzi1, M A Rafi, M Zaka, M Curtis, M T Vanier, D A Wenger.   

Abstract

Globoid cell leukodystrophy (Krabbe disease) is a severe leukodystrophy caused by mutations in the galactocerebrosidase (GALC) gene leading to extremely low (less than 5% of normal activity) GALC activity. Human patients include primarily severely affected infants as well as patients with a later onset of symptoms. The infants usually die before 2 years of age, but it is difficult to predict the clinical course in older patients. In addition to these patients, additional individuals identified in this laboratory have 10--20% of normal GALC activity measured in accessible tissues. These individuals have a wide range of clinical presentations involving neurological degeneration. On molecular analysis of the GALC gene they all have three or more mutations considered to be normal polymorphisms resulting in amino acid changes in the two copies of the GALC gene. In order to investigate the role these amino acid changes may play on clinical, biochemical, and pathological findings, a new transgenic mouse was generated by homologous recombination. After preliminary studies determined what effect each amino acid change had on mouse GALC activity in transient transfection experiments, mice containing a cysteine residue at codon 168 instead of histidine (H168C) were produced. These mice developed symptoms, but they were delayed by 10--15 days from the well-characterized twitcher (twi) mouse. They accumulated psychosine slightly slower than twi mice, showed pathological changes less severe than twi mice in the central and peripheral nervous systems, and live about 15 days longer than twi mice. They have large litters and will play a role in therapy trials using new procedures currently under development. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461188     DOI: 10.1006/mgme.2001.3194

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

1.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

Review 2.  Treatment for Krabbe's disease: Finding the combination.

Authors:  Christina R Mikulka; Mark S Sands
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Biochemical, cell biological, pathological, and therapeutic aspects of Krabbe's disease.

Authors:  Je-Seong Won; Avtar K Singh; Inderjit Singh
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 4.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

Review 5.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

6.  Missense mutation in mouse GALC mimics human gene defect and offers new insights into Krabbe disease.

Authors:  Gregory B Potter; Marta Santos; Muriel T Davisson; David H Rowitch; Dan L Marks; Ernesto R Bongarzone; Magdalena A Petryniak
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

7.  Macrophages counteract demyelination in a mouse model of globoid cell leukodystrophy.

Authors:  Yoichi Kondo; Jessica M Adams; Marie T Vanier; Ian D Duncan
Journal:  J Neurosci       Date:  2011-03-09       Impact factor: 6.167

8.  Generation of transgenic mice expressing insulin-like growth factor-1 under the control of the myelin basic protein promoter: increased myelination and potential for studies on the effects of increased IGF-1 on experimentally and genetically induced demyelination.

Authors:  Paola Luzi; Mariam Zaka; Han Zhi Rao; Mark Curtis; Mohammad A Rafi; David A Wenger
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 9.  Interferons, signal transduction pathways, and the central nervous system.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

10.  Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy.

Authors:  Paola Luzi; Ronnie M Abraham; Mohammad A Rafi; Mark Curtis; D Craig Hooper; David A Wenger
Journal:  Brain Res       Date:  2009-09-11       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.